Edition:
United States

Allergan plc (AGN)

AGN on New York Consolidated

216.30USD
18 Jan 2017
Change (% chg)

$1.52 (+0.71%)
Prev Close
$214.78
Open
$216.50
Day's High
$219.13
Day's Low
$214.70
Volume
1,018,688
Avg. Vol
4,719,085
52-wk High
$301.98
52-wk Low
$184.50

Select another date:

Tue, Jan 17 2017

Allergan to pay $15 mln over failing to disclose merger talks

WASHINGTON A unit of Botox maker Allergan Plc will pay a $15 million penalty and admit to wrongdoing, after U.S. regulators on Tuesday accused the unit of failing to disclose 2014 merger talks with Actavis, the U.S. Securities and Exchange Commission said.

Allergan to pay $15 million over failing to disclose merger talks

WASHINGTON A unit of Botox maker Allergan Plc will pay a $15 million penalty and admit to wrongdoing, after U.S. regulators on Tuesday accused the unit of failing to disclose 2014 merger talks with Actavis, the U.S. Securities and Exchange Commission said.

UPDATE 1-Allergan to pay $15 mln over failing to disclose merger talks

WASHINGTON, Jan 17 A unit of Botox maker Allergan Plc will pay a $15 million penalty and admit to wrongdoing, after U.S. regulators on Tuesday accused the unit of failing to disclose 2014 merger talks with Actavis, the U.S. Securities and Exchange Commission said.

Allergan to pay $15 mln over failing to disclose merger talks

WASHINGTON, Jan 17 Botox maker Allergan plc will pay a $15 million penalty and admit to wrongdoing, after U.S. regulators on Tuesday accused the company of failing to disclose merger talks with Actavis, the U.S. Securities and Exchange Commission said.

BRIEF-Richter, Allergan announce positive uterine fibroid medicine test

* Hungary's Richter and Allergan announce positive phase III clinical test results for new medicine to treat uterine fibroids.

BRIEF-Allergan CEO says company wants to create more jobs in the U.S.

* Says "Allergan is aligned with the priorities of the incoming Trump administration"

BRIEF-Allergan enters parkinson's disease through option arrangement with Lysosomal Therapeutics

* Allergan enters parkinson's disease through option arrangement with Lysosomal Therapeutics Inc (LTI) for its potential first-in-class breakthrough compounds

BRIEF-Allergan enters into licensing agreement with Assembly Biosciences

* Will make upfront payment to assembly of $50 million for exclusive, worldwide rights to develop and commercialize UC, CD and IBS compounds

Allergan expects mid-single digit 2017 revenue growth

Allergan Plc , taking a more "realistic" approach to its forecast, said on Thursday it expects mid-single digit net revenue percentage growth this year, helped by key products and new launches.

Allergan to buy Acelity's tissue unit LifeCell for $2.9 billion

Drugmaker Allergan Plc said on Tuesday it would buy LifeCell, a regenerative medicine unit owned by privately held Acelity LP Inc, for $2.9 billion in cash, bringing the number of deals it has made this year to an even dozen.

Select another date: